8 results about "Mammal" patented technology

Described herein are methods of inhibiting M-CSF activity, and, in particular, M-CSF/c-fms dependent cell signaling. In a first embodiment of the invention, one administers to a mammal viral vectors that deliver genes experessing antisense c-fms RNA; in a second embodiment, one induces in vivo production of a high-affinity soluble c-fms protein that competes for non-bound M-CSF; in a third embodiment, one administers a ribozyme-viral vector against c-fms mRNA; and in a fourth embodiment, one administers oligodeoxynucleotides that inhibit expression of c-fms gene product. The methods may be used to treat any disease in which M-CSF activity plays a role, and are particularly effective in treating and preventing atherosclerosis.

Embodiments of the present invention are directed primarily, but not exclusively, to a method for treating and preventing cardiovascular disease by inhibiting receptors to M-CSF. Other embodiments of the present invention include any and all biologic and/or pathobiologic phenomena mediated in whole or in part by M-CSF signaling through its receptor. Pathobiologic phenomena include, but are not limited to, disease entities such as osteoporosis, Alzheimer's disease, diabetes mellitus (Type 1 and/or Type 2), infectious diseases, cancer, and inherited disorders characterized by defects in one or more components in the M-CSF signaling pathway.

The present invention provides data to demonstrate that the re-fusion, of a mammalian karyoplast to an enucleated in vivo ovulated cocyte, following an unsuccessful initial simultaneous electrical fusion and activation event offers an additional alternative and improvement in the creation of activated and fused nuclear transfer-capable embryos for the production of live off-spring in various mammalian non-human species including goats, pigs, rodents, primates, rabbits and cattle. Additionally, multiple electrical pulses offers an alternative and more efficient activation method in a simultaneous fusion and activation methodology for viable offspring production in a animal nuclear transfer program.

A method of preparation of a treated Spirulina compound includes the steps of rehydrating desiccated Spirulina, stressing the culture and freeze drying to a powder. The resultant compound has activity as an anti-viral compound and an anti-bacterial compound. It is capable of effecting repair of skin defects in mammals and acting as a preventative agent to skin defects.

This invention relates to an osteogenic device for the de novo induction of bone formation in a mammal. The device contains a at least one transforming growth factor—&bgr;3 isoform and a retention matrix. The device is introduced by direct injection or surgical implantation into an area where de novo bone formation is desired and, once implanted, the retention matrix acts to retain the TGF-&bgr;3 isoform at its place of introduction and forms a scaffold for generated bone, the induction of which is promoted by the TGF-&bgr;3 isoform. The device may be used to induce bone growth where bone has been debrided in a surgical procedure and it may also be used to transform neoplastic primary and/or metastatic secondary masses into bone thus facilitating surgical debridement thereof.

The invention discloses an in-vitro heart constant pressure/constant flow perfusion experiment device for cardiological mammals. The device comprises a fixing and supporting device, a perfusion device and a monitoring device. The fixing and supporting device comprises a bottom platform. A fixed supporting plate and a movable supporting plate are arranged at the rear side of the bottom platform. A hydraulic lifter is arranged below the movable supporting plate. The perfusion device comprises a baffling perfusion column, and the baffling perfusion column is fixedly arranged on the front face of the movable supporting plate. The bottom of the baffling perfusion column is connected with the heart, and a conical incubator and a blood filter are sequentially arranged below the heat. The right side of the blood filter is connected with an oxygenator, and the oxygenator is connected with a gas storage bottle, a liquid storage bottle and a peristaltic pump through a gas conveying pipe, a liquid replenishing pipe and a liquid conveying pipe, respectively. The tail end of the liquid conveying pipe is connected with a liquid inlet of the baffling perfusion column. The baffling perfusion column and the conical incubator are connected with a temperature controller by means of a manifold. The monitoring device collects and records the test data through an electrode, a balloon, a heart sound transducer and a pressure transducer.

Genomic instability in T-antigen expressing cells can be overcome by modifying the gene expressing T-antigen so that it lacks Bub1 binding. Stable cell lines can be produced by incorporation of the modified T-antigen gene, preferably together with the catalytic sub-unit of the telomerase construct.